Program
birelentinib
Also written as “DZD8586”, “Birelentinib” and “DZD8586+R-CHOP”.
Its studies are mostly in Lymphoma, Non-Hodgkin · Lymphoma, Large B-Cell, Diffuse · Leukemia, Lymphocytic, Chronic, B-Cell · Purpura, Thrombocytopenic, Idiopathic, led by Dizal Pharmaceuticals.
Furthest: phase 3, since Aug 18, 202512 company-led studies, 7 open or runningNext primary completion: Nov 23, 2026 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Dizal Pharmaceuticals | 127 open or running | phase 3since Aug 18, 2025 | Dec 15, 2021 | Nov 23, 2026phase 1 · NCT07888569 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Dec 15, 2021First study: phase 1 study in Lymphoma, Non-HodgkinFirst studyNCT05176873 · 64 enrolled · United States
- Mar 30, 2023Phase 1 study in Lymphoma, Non-HodgkinNCT05824585 · 17 enrolled · United States, Australia
- Apr 25, 2023Phase 2 study in Lymphoma, Non-HodgkinNCT05844956 · 17 enrolled · China
- Aug 1, 20242 phase 2 studiesNCT06539195, NCT06539182
- Jun 16, 2025Phase 2 study in Lymphoma, Large B-Cell, DiffuseNCT07059650 · 150 planned · China
- Aug 18, 2025Phase 2 study in Leukemia, Lymphocytic, Chronic, B-CellNCT07154264 · 66 planned · China
- Aug 18, 2025Phase 3 study in Leukemia, Lymphocytic, Chronic, B-CellNCT07139873 · 250 planned · China
- Dec 8, 2025Phase 2 study in Purpura, Thrombocytopenic, IdiopathicNCT07294365 · 60 planned · China
- Jan 26, 2026Phase 1 study in Lymphoma, Non-HodgkinNCT07454863 · 6 enrolled · China
- Jul 14, 2026Phase 3 study in Lymphoma, Large B-Cell, DiffuseNCT07712588 · 880 planned · China
- Sep 30, 2026Phase 1 study in HealthyNCT07888569 · 26 planned · China
Ahead
- Nov 23, 2026Primary completion: phase 1 study in HealthyNCT07888569
- Jul 2027Primary completion: phase 2 study in Purpura, Thrombocytopenic, IdiopathicNCT07294365
- Sep 2027Primary completion: phase 2 study in Leukemia, Lymphocytic, Chronic, B-CellNCT06539182
- Jan 2029Primary completion: phase 3 study in Leukemia, Lymphocytic, Chronic, B-CellNCT07139873
TargetBeta
“An orally bioavailable non-covalent dual inhibitor of tyrosine-protein kinases Lyn (LYN) and BTK (Bruton's tyrosine kinase; Bruton agammaglobulinemia tyrosine kinase), ”NCIt, by rule
Studies
All 12 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07888569Healthy · China | 1 | Recruiting | Nov 23, 2026 | 26 |
| NCT07712588Lymphoma, Large B-Cell, Diffuse · China | 3 | Not yet recruiting | Jan 2031 | 880 |
| NCT07454863Lymphoma, Non-Hodgkin · China | 1 | Completed | Mar 27, 2026 | 6 |
| NCT07294365Purpura, Thrombocytopenic, Idiopathic · China | 2 | Recruiting | Jul 2027 | 60 |
| NCT07154264Leukemia, Lymphocytic, Chronic, B-Cell · China | 2 | Recruiting | Dec 2029 | 66 |
| NCT07139873Leukemia, Lymphocytic, Chronic, B-Cell · China | 3 | Recruiting | Jan 2029 | 250 |
| NCT07059650Lymphoma, Large B-Cell, Diffuse · China | 2 | Recruiting | Oct 2030 | 150 |
| NCT06539195Lymphoma, Large B-Cell, Diffuse · China | 2 | Completed | Jun 10, 2026 | 59 |
| NCT06539182Leukemia, Lymphocytic, Chronic, B-Cell · China | 2 | Recruiting | Sep 2027 | 155 |
| NCT05844956Lymphoma, Non-Hodgkin · China | 2 | Completed | Feb 29, 2024 | 17 |
| NCT05824585Lymphoma, Non-Hodgkin · United States, Australia | 1 | Completed | Jun 30, 2025 | 17 |
| NCT05176873Lymphoma, Non-Hodgkin · United States | 1 | Completed | May 11, 2022 | 64 |
How it is read
Names in the registry
- “DZD8586”, 13 entries
- “Birelentinib”, 1 entry
- “DZD8586+R-CHOP”, 1 entry
- “DZD8586+R-GemOx”, 1 entry
- “DZD8586+BR”, 1 entry
Conditions, from the studies’ own filings
- Lymphoma, Non-Hodgkin, 4 studies
- Lymphoma, Large B-Cell, Diffuse, 3 studies
- Leukemia, Lymphocytic, Chronic, B-Cell, 3 studies
- Purpura, Thrombocytopenic, Idiopathic, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.